154 related articles for article (PubMed ID: 37307773)
1. The long-term psychosocial consequences of screen-detected ductal carcinoma in situ and invasive breast cancer.
Gram EG; Manso TFR; Heleno B; Siersma V; Á Rogvi J; Brodersen JB
Breast; 2023 Aug; 70():41-48. PubMed ID: 37307773
[TBL] [Abstract][Full Text] [Related]
2. The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
Théberge I; Vandal N; Guertin MH; Perron L
Breast Cancer Res Treat; 2019 Apr; 174(2):525-535. PubMed ID: 30564969
[TBL] [Abstract][Full Text] [Related]
3. Trends in detection of invasive cancer and ductal carcinoma in situ at biennial screening mammography in Spain: a retrospective cohort study.
Román M; Rué M; Sala M; Ascunce N; Baré M; Baroja A; De la Vega M; Galcerán J; Natal C; Salas D; Sánchez-Jacob M; Zubizarreta R; Castells X;
PLoS One; 2013; 8(12):e83121. PubMed ID: 24376649
[TBL] [Abstract][Full Text] [Related]
4. Reoperation Rates in Ductal Carcinoma In Situ vs Invasive Breast Cancer After Wire-Guided Breast-Conserving Surgery.
Langhans L; Jensen MB; Talman MM; Vejborg I; Kroman N; Tvedskov TF
JAMA Surg; 2017 Apr; 152(4):378-384. PubMed ID: 28002557
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
6. Modeling the natural history of ductal carcinoma in situ based on population data.
Chootipongchaivat S; van Ravesteyn NT; Li X; Huang H; Weedon-Fekjær H; Ryser MD; Weaver DL; Burnside ES; Heckman-Stoddard BM; de Koning HJ; Lee SJ
Breast Cancer Res; 2020 May; 22(1):53. PubMed ID: 32460821
[TBL] [Abstract][Full Text] [Related]
7. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
[TBL] [Abstract][Full Text] [Related]
8. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
9. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis.
Ploumen RAW; Claassens EL; Kooreman LFS; Keymeulen KBMI; van Kats MACE; Gommers S; Siesling S; van Nijnatten TJA; Smidt ML
Breast Cancer Res Treat; 2023 Sep; 201(2):227-235. PubMed ID: 37395816
[TBL] [Abstract][Full Text] [Related]
10. Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer.
Afghahi A; Forgó E; Mitani AA; Desai M; Varma S; Seto T; Rigdon J; Jensen KC; Troxell ML; Gomez SL; Das AK; Beck AH; Kurian AW; West RB
Breast Cancer Res; 2015 Aug; 17(1):108. PubMed ID: 26265211
[TBL] [Abstract][Full Text] [Related]
11. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
[TBL] [Abstract][Full Text] [Related]
12. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
[TBL] [Abstract][Full Text] [Related]
13. Germline Genetic Testing Among Women ≤ 45 Years of Age with Ductal Carcinoma In Situ Versus Invasive Breast Cancer in a Large Integrated Health Care System.
Hsu DS; Jiang SF; Habel LA; Hoodfar E; Karlea A; Manace-Brenman L; Dzubnar JM; Shim VC
Ann Surg Oncol; 2023 Oct; 30(11):6454-6461. PubMed ID: 37386303
[TBL] [Abstract][Full Text] [Related]
14. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
15. Cumulative 6-Year Risk of Screen-Detected Ductal Carcinoma In Situ by Screening Frequency.
Sprague BL; Chen S; Miglioretti DL; Gard CC; Tice JA; Hubbard RA; Aiello Bowles EJ; Kaufman PA; Kerlikowske K
JAMA Netw Open; 2023 Feb; 6(2):e230166. PubMed ID: 36808238
[TBL] [Abstract][Full Text] [Related]
16. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.
Sanders ME; Schuyler PA; Dupont WD; Page DL
Cancer; 2005 Jun; 103(12):2481-4. PubMed ID: 15884091
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
Koh VC; Lim JC; Thike AA; Cheok PY; Thu MM; Tan VK; Tan BK; Ong KW; Ho GH; Tan WJ; Tan Y; Salahuddin AS; Busmanis I; Chong AP; Iqbal J; Thilagaratnam S; Wong JS; Tan PH
Breast Cancer Res Treat; 2015 Jul; 152(2):293-304. PubMed ID: 26077641
[TBL] [Abstract][Full Text] [Related]
18. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
[TBL] [Abstract][Full Text] [Related]
19. Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.
Alaeikhanehshir S; Voets MM; van Duijnhoven FH; Lips EH; Groen EJ; van Oirsouw MCJ; Hwang SE; Lo JY; Wesseling J; Mann RM; Teuwen J;
Cancer Imaging; 2024 Apr; 24(1):48. PubMed ID: 38576031
[TBL] [Abstract][Full Text] [Related]
20. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
